WPD Pharmaceuticals Inc. announced that it has received the final version of the signed Consortium Agreement related to the EuroNanoMed Project. The consortium will research the potential of AGuIX® nanoparticles in maximizing radiotherapy efficiency and explore two of WPD's compounds specifically to restore GBM cells' sensitivity to radiotherapy. The consortium is coordinated by Dr. Muriel Barberi-Heyob from the Research Center for Automatic Control (CRAN), a joint research unit between the University of Lorraine and the French National Scientific Research Center (CNRS) - Institute for Information Sciences and Technologies, and has been successfully funded by EuroNanoMed III "European Innovative Research & Technological Development Projects in Nanomedicine" project - "RXnanoBRAIN Nanoparticles to optimize the effects of radiotherapy of brain tumors: Multi-scale modeling and experimental validation".

Along with WPD's Dr. Beata Pajak, the consortium includes Oslo University Hospital (Norway) represented by Dr. Kristian Berg, NH TherAguix (France) company represented by Dr. Sandrine Dufort, and Jagiellonian University in Krakow (Poland) represented by Dr. Martyna Elas. Over the three-year project timeline, the consortium aims to plan and adapt the X-ray doses given to the patient to maximize radiotherapy efficiency on these high-grade tumors while preserving the adjacent healthy tissue. This project will base its work on pre-clinical experiments at different biological scales (cells, tissues, and in vivo on rodent models) and algorithms' development.

An evaluation will then be carried out of the therapeutic potential of an innovative nanoparticle which results from the discovery of NH TherAguix, which is currently in clinical development. Researchers will study the complementarity and effectiveness of the energy of radiotherapy and nanoparticles (NPs) within the tumor tissue. Gaining an in-depth understanding of the effects on the immune response to control and comprehensively enhance the potential of the effects of this treatment also represents a crucial innovative step for the project.